Michael H. Davidson sold $14.8M of NewAmsterdam Pharma (NAMS)

Executed Mar 2, disclosed Mar 2, the same day.

Value, as filed

$14.8M

443,707 sh × $33.25

Executed

Mar 2

the trade date, as filed

Disclosed

Mar 2

0 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Michael H. Davidson Chief Executive Officer profile →

Michael H. Davidson (Chief Executive Officer) filed 4 Form 4 reports in the trailing twelve months (1 purchase, 3 sales), most often in NewAmsterdam Pharma Company N.V. (NAMS). Across 1 priced purchase filing, the average 21-session return was -7.4% from execution and -9.5% from disclosure (delay-adjusted; derived). The largest single filing was $14.8M of NAMS (443,707 sh × $33.25, as filed), executed Mar 2.

The name

NAMS

NewAmsterdam Pharma Company N.V. NAMS · Healthcare · 45 filings in 24 months ticker →

Healthcare · NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with ca…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Michael H. Davidson in NAMS

NAMSPURCHASE NewAmsterdam Pharma Company N.V. $226K
10,000 sh × $22.65
Exec Sep 14
Filed Sep 15 · 4:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $10.5M
304,993 sh across 6 lots
Exec Feb 24
Filed Feb 26 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $411K
as filed
Exec Jan 7
Filed Jan 9 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $277K
as filed
Exec Mar 26 2025
Filed Mar 28 2025 · 5:30 PM ET